{"title":"A Report on Regulatory Authority","authors":"Suprita A. Tawde","doi":"10.35248/2329-6887.21.9.305","DOIUrl":null,"url":null,"abstract":"*Corresponding Author: Suprita Tawde, Research Scientist, Akorn Pharmaceuticals Inc., USA Tel: +91 8549965414, Emailtawades@ gmail.com Received: March 6, 2021; Accepted: March 20, 2021; Published: March 27, 2021 Citation: Tawde S (2021) A Report on Regulatory Authority, J. Pharamacovigil. 9:305. doi-10.35248/2329-6887.21.9.305. Copyright: ©2021 Tawde S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The drug business is one of the exceptionally directed enterprises, with numerous standards and guidelines upheld by the public authority to secure the wellbeing and prosperity of general society. In this manner, the point of the drug business is to recognize and build up a conventional medication item which can be customized to meet the assorted market necessities. After the presentation of the item patent system in India, there was a requirement for drug organizations both in India and abroad to investigate fresher business sectors. Indian pharma majors are entering new business sectors with worldwide desire, consolidations and acquisitions are in concentration with motivation to enter new market.","PeriodicalId":16958,"journal":{"name":"Journal of Pharmacovigilance","volume":"1 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacovigilance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2329-6887.21.9.305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
关于监管机构的报告
*通讯作者:Suprita Tawde,研究科学家,Akorn制药公司,美国电话:+91 8549965414,emailtawades@gmail.com收稿日期:2021年3月6日;录用日期:2021年3月20日;发布日期:2021年3月27日引文:Tawde S (2021) A Report on Regulatory Authority, J. Pharamacovigil. 9:305。doi: 10.35248/2329 6887.21.9.305。版权所有:©2021 Tawde S.这是一篇根据知识共享署名许可条款发布的开放获取文章,允许在任何媒体上不受限制地使用、分发和复制,前提是注明原作者和来源。制药业是受到特别指导的企业之一,有许多标准和准则得到公共当局的支持,以确保整个社会的福祉和繁荣。在这种情况下,药品业务的重点是识别和建立一个常规的药物项目,可以定制以满足各种市场需求。在印度提出项目专利制度后,要求印度和国外的药品组织调查新的商业部门。印度制药巨头正怀着全球的愿望进入新的业务领域,整合和收购正在集中,并有进入新市场的动力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。